CTRI/2021/01/030250
Not yet recruiting
未知
Medication Therapy Management on Anticoagulants and Incorporation of Pharmacogenetics-Guided Individualized Dosing of Warfarin
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: D683- Hemorrhagic disorder due to circulating anticoagulants
- Sponsor
- Manipal Academy of Higher Education
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients prescribed with anticoagulants in surgery, cardio\-thoracic and cardiology units (Both in\-patients and out\-patients)
Exclusion Criteria
- •Critically ill patients
- •Patients with psychiatric problems
- •Pregnant women
- •Patients not willing to participate in the study
- •For PGx study: Other anticoagulants, inhibitors and inducers of warfarin excluded
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associated with de novo atrial Fibrillation Arrhythmia (SCA-FA): A prospective multicenter study2024-515433-15-02Centre Hospitalier De Pau500
Completed
Not Applicable
Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in acute cardioembolic stroke with nonvalvular atrial fibrillation.cerebral infarctionJPRN-UMIN000010477Department of Neurology, Kansai Medical University50
Recruiting
Not Applicable
Efficacy and safety of anticoagulant treatment using New oral anticoagulant (edoxaban) in atrial fibrillation after cardiac surgery.arterial fibrillation after cardiac surgery (nonvalvular disease)JPRN-UMIN000021138ihon University school of medicine150
Not yet recruiting
Not Applicable
The efficacy and safety of anticoagulant therapy Arixtra Injection for the prevention of the vein thromboembolism in laparoscopic colorectal surgerycolorectal cancerJPRN-UMIN000007005Osaka Medical College200
Not yet recruiting
Phase 3
Effectiveness and safety of blood thinning agent (Anticoagulation) in patients with dying limb with poor blood supply (Digital Gangrene) and an underlying immune system related disease (Connective Tissue Disease)Health Condition 1: M339- Dermatopolymyositis, unspecifiedHealth Condition 2: M319- Necrotizing vasculopathy, unspecifiedHealth Condition 3: M340- Progressive systemic sclerosisHealth Condition 4: M368- Systemic disorders of connective tissue in other diseases classified elsewhereHealth Condition 5: M359- Systemic involvement of connectivetissue, unspecifiedHealth Condition 6: M321- Systemic lupus erythematosus withorgan or system involvementCTRI/2024/03/063481Department of Clinical Immunology & Rheumatology